Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTB-9655 in advanced solid tumors
NCT04990739Phase 1Unknown
- Sponsor
- Metabomed
- Start
- Jun 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of MTB-9655 in solid tumor (advanced stage), sponsored by Metabomed. Primary endpoints: Dose Limiting Toxicities at 21 days, Maximum Tolerated Dose at 21 days and 2 more. Status: unknown.
02
Drugs
MTB-9655
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04990739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990739.